Background: Breast cancer survival varies widely across middle‐income settings and may be influenced by clinical stage at diagnosis and access pathways within oncology care networks. In Brazil, evidence from statewide cohorts using linked registry and mortality data remains limited. Aim: To investigate the association between clinical factors and breast cancer–specific survival among women treated in all hospitals comprising the Oncology Care Network of a state in Southeastern Brazil. Methods and Results: A retrospective cohort study was conducted using data from the Hospital Cancer Registry linked to the state Mortality Information System. Women aged ≥ 18 years diagnosed with primary breast cancer (ICD‐10: C50.x) between 2000 and 2016 were included and followed until December 31, 2021. Five‐year breast cancer–specific survival was estimated using the Kaplan–Meier method, and factors associated with mortality were assessed using cause‐specific Cox proportional hazards models with complete‐case analysis. A total of 12,096 women were included, of whom 7,191 had complete data for multivariable analysis. The mean age at diagnosis was 54.7 years. Five‐year breast cancer–specific survival ranged from 97% (95% CI: 96−97%) in stage I to 32% (95% CI: 31−37%) in stage IV. Women referred from the private healthcare system had a significantly lower risk of breast cancer mortality than those referred from the public system (HR: 0.83; 95% CI: 0.75−0.93; p = 0.001). Advanced clinical stage remained the strongest predictor of mortality, and the presence of distant metastasis at diagnosis increased the risk of breast cancer death by 49% (HR: 1.49; 95% CI: 1.14−1.94; p = 0.003). Conclusion: Breast cancer–specific survival in Espírito Santo is strongly determined by stage at diagnosis and by differential access pathways within the oncology care network. Strengthening early diagnostic strategies, improving referral coordination, and ensuring equitable access to timely treatment are essential to reduce survival disparities in this setting.
1 January 2025 in Revista Brasileira de Enfermagem
Objectives: to describe and analyze the most prevalent cancer symptom clusters as well as their intensity, discomfort and clustering in hospitalized women with non-metastatic malignant breast cancer.
15 February 2024 in Revista de Enfermagem UFPE on line
Objetivo: Descrever o perfil clínico-epidemiológico de pacientes com câncer indicados para quimioterapia ambulatorial. Método: Estudo observacional descritivo realizado com pacientes oncológicos encaminhados para quimioterapia ambulatorial em um hospital de referência no tratamento do câncer no Sudeste do Brasil. As informações sociodemográficas, clínicas e relacionadas às características dos tumores foram obtidas por meio de questionário e consulta aos prontuários médicos. Realizou-se análise estatística descritiva dos dados. Resultados: Foram analisados 84 pacientes, dos quais a maioria era composta por mulheres (72,62%). A faixa etária predominante foi de 50 a 64 anos (42,86%). A maioria dos pacientes se declarou de cor parda (40,48%), tinha renda mensal de um salário mínimo (45,24%), ensino fundamental completo (48,81%) e era casada (51,19%). A maior parte não possuía plano de saúde (82,14%). A neoplasia maligna da mama foi a mais comum, frequentemente diagnosticada no estágio II (57,14%). A quimioterapia foi o tratamento predominante (57,14%). Conclusão: O perfil sociodemográfico e clínico identificado neste estudo evidenciou a complexidade multifatorial, histológica e hematológica associada ao câncer. Para um melhor prognóstico, é fundamental avaliar variáveis sociodemográficas e clínicas, além de monitorar biomarcadores inflamatórios por meio do hemograma durante os ciclos de quimioterapia, garantindo um acompanhamento mais eficaz desses pacientes.
Introduction: Cancer imposes substantial physical and psychological burdens that negatively affect patients’ health-related quality of life (HRQoL). Assessing HRQoL prior to chemotherapy initiation is essential for tailoring early supportive care strategies. Objective: To describe the characteristics and identify the factors associated with HRQoL in newly diagnosed cancer patients immediately before initiating outpatient chemotherapy. Method: This cross-sectional study included adults with newly diagnosed stage I–III cancer scheduled to begin outpatient chemotherapy at a Brazilian cancer referral center. Sociodemographic and tumor-related data were obtained using a structured questionnaire. HRQoL was assessed with the EQ-5D-3L instrument. Descriptive and bivariate analyses were performed using Fisher's exact test. Results: Eighty-four patients were included (mean age: 57.68 years); most were female (72.62%), of mixed ethnicity (40.48%), had completed only primary education (48.81%), and were married (51.19%). The average time from diagnosis to treatment initiation was 120 days, and 60.71% reported comorbidities. Breast cancer was the most common diagnosis (57.14%), predominantly at Stage II (57.14%). The mean EQ-5D-3L index score was 77.79. Comorbidities were significantly associated with impaired mobility ( p = .009), and female patients reported significantly more anxiety and depression than males ( p = .005). Inflammatory markers revealed that most patients had low neutrophil-to-lymphocyte ratio (76.54%), low platelet-to-lymphocyte ratio (72.84%), and elevated C-reactive protein (CRP; 84.52%). In the multivariate analysis, the presence of comorbidities remained significantly associated with worse mobility (OR = 5.456; 95% CI [1.205–24.707]; p = .028), and male sex was independently associated with lower levels of anxiety and depression (OR = 0.206; [0.067–0.634]; p = .006). A nonsignificant trend was also observed between higher CRP levels and increased pain (OR = 2.800; [0.824–9.510]; p = .099). Conclusions: Patients with newly diagnosed cancer experience impaired HRQoL even before starting chemotherapy. Comorbidities were associated with worse mobility, and female patients reported higher levels of anxiety and depression. These findings support the need for early multidisciplinary care to mitigate functional and emotional burdens prior to treatment.
1 January 2025 in Revista Brasileira de Enfermagem
Objetivos: descrever e analisar os sintomas oncológicos mais prevalentes, bem como sua intensidade, incômodo e clusterização em mulheres com neoplasia maligna da mama não metastático hospitalizadas.
1 January 2026 in Revista Latino-Americana de Enfermagem
Objective: to assess the clinical, inflammatory and electrocardiographic profile of cancer patients undergoing the Pre-chemotherapy phase, with the purpose of early identifying cardiovascular toxicity indicative signs. Method: an observational and cross-sectional study, conducted between November2022 and December2023 with adult cancer patients in stagesI toIII treated at a hospital from southern Brazil. Sociodemographic, clinical and tumor-related data were collected, in addition to laboratory and electrocardiographic tests performed before the first chemotherapy infusion. Descriptive analyses were carried out in the Rsoftware. Results: the participants were 84 patients, mostly women (72.6%) with breast cancer diagnoses(57.1%). Prevalence of systemic inflammation was verified, with high C-reactive protein in 35.7% and increased neutrophil-lymphocyte and platelet-lymphocyte ratios in 23.5% and 27.2%, respectively. A significant association was observed between high Body Mass Index and T-wave alterations (p=0.005). Although 10 patients presented prolonged corrected QT intervals, no other statistically significant associations were identified. Conclusion: the pre-chemotherapy phase revealed relevant inflammatory and electrocardiographic alterations, even in the absence of installed cardiotoxicity. The findings reinforce the importance of baseline cardiovascular evaluations and of multi-professional follow-up in Cardio-Oncology, especially for patients with modifiable risk factors. Longitudinal studies are recommended to elucidate the clinical and prognostic evolution of these alterations.